Sign in

    Isabella Camaj • Evercore ISI

    Isabella Camaj's questions to Alkami Technology Inc (ALKT) leadership

    Isabella Camaj's questions to Alkami Technology Inc (ALKT) leadership • Q2 2025

    Question

    Isabella Camaj of JPMorgan Chase & Co. inquired about the specific customer types most attracted to the Mantle cross-sell and which products are supporting wins with regional banking customers.

    Answer

    CEO Alex Shootman explained that the demand for Mantle is broad-based, driven by a universal need for financial institutions to attract low-cost core deposits in the current rate environment. For regional banks specifically, he highlighted the strength of the Mantle onboarding solution, ACH Alert and Positive Pay products, and the ongoing build-out of treasury management capabilities.

    Ask Fintool Equity Research AI

    Isabella Camaj's questions to Atea Pharmaceuticals Inc (AVIR) leadership

    Isabella Camaj's questions to Atea Pharmaceuticals Inc (AVIR) leadership • Q4 2024

    Question

    Isabella Camaj of Evercore ISI inquired about any specific guidance from the FDA regarding the Phase III trial design and the expected scope of the upcoming Phase II data readout.

    Answer

    Dr. Janet Hammond, Chief Development Officer, responded that the FDA is fully aligned with Atea's open-label Phase III trial approach and had no substantive comments. Dr. Arantxa Horga, Chief Medical Officer, added that more detailed Phase II data, including safety information, will be presented at a medical meeting in the summer.

    Ask Fintool Equity Research AI